Damiano Rondelli

Damiano Rondelli

Auto-generated profile, based on publicly available information

Damiano Rondelli

Division of Hematology and Oncology, University of Illinois Chicago, Chicago, IL 60607, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2005 in Blood
Verified
Journal Article
Closed access
PDF file
DRDamiano Rondelli
Damiano Rondelli
GBGiovanni Barosi
Giovanni Barosi
ABAndrea Bacigalupo
Andrea Bacigalupo
JPJosef T. Prchal
Josef T. Prchal
UPUday Popat
Uday Popat
RHRonald Hoffman
Ronald Hoffman
A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen. The patients received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1 Ag-mismatched related (n = 1), donors. RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1). At the time of transplantation, all of the patients were at intermediate (n = 13) or high (n = 8) risk, according to the Dupriez classification. Of the patients, 19 had grade III or IV marrow fibrosis. All of the patients achieved full engraftment but one. Posttransplantation chimerism analysis showed more than 95% donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. There were 3 patients who died from acute GVHD, infection, and relapse. There are 18 patients alive 12 to 122 months (median, 31 months) after transplantation, and 17 are in remission (1 after a second transplantation). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.

1 March 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SSSantosh Saraf
Santosh Saraf
AOAnnie L. Oh
Annie L. Oh
PPPritesh R. Patel
Pritesh R. Patel
YJYash Jalundhwala
Yash Jalundhwala
KSKaren Sweiss
Karen Sweiss
DRDamiano Rondelli
Damiano Rondelli
Allogeneic hematopoietic stem cell transplantation (HSCT) is rarely performed in adult patients with sickle cell disease (SCD). We utilized the chemotherapy-free, alemtuzumab/total body irradiation 300 cGy regimen with sirolimus as post-transplantation immunosuppression in 13 high-risk SCD adult patients between November 2011 and June 2014. Patients received matched related donor (MRD) granulocyte colony-stimulating factor-mobilized peripheral blood stem cells, including 2 cases that were ABO incompatible. Quality-of-life (QoL) measurements were performed at different time points after HSCT. All 13 patients initially engrafted. A stable mixed donor/recipient chimerism was maintained in 12 patients (92%), whereas 1 patient not compliant with sirolimus experienced secondary graft failure. With a median follow-up of 22 months (range, 12 to 44 months) there was no mortality, no acute or chronic graft-versus-host disease (GVHD), and no grades 3 or 4 extramedullary toxicities. At 1 year after transplantation, patients with stable donor chimerism have normalized hemoglobin concentrations and improved cardiopulmonary and QoL parameters including bodily pain, general health, and vitality. In 4 patients, sirolimus was stopped without rejection or SCD-related complications. These results underscore the successful use of a chemotherapy-free regimen in MRD HSCT for high-risk adult SCD patients and demonstrates a high cure rate, absence of GVHD or mortality, and improvement in QoL including the applicability of this regimen in ABO mismatched cases (NCT number 01499888).

14 August 2014 in Blood
Verified
Journal Article
Open access
PDF file
DRDamiano Rondelli
Damiano Rondelli
JGJudith D. Goldberg
Judith D. Goldberg
LILuis Isola
Luis Isola
LPLeah S. Price
Leah S. Price
TSTsiporah B. Shore
Tsiporah B. Shore
RHRonald Hoffman
Ronald Hoffman
Key Points: A high survival rate was seen in primary or secondary MF patients transplanted from matched related donors using the FluMel regimen. FluMel plus ATG in HSCT from unrelated donors for MF patients is associated with an increased risk of graft failure.

1 August 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SSSantosh Saraf
Santosh Saraf
AOAnnie L. Oh
Annie L. Oh
PPPritesh R. Patel
Pritesh R. Patel
KSKaren Sweiss
Karen Sweiss
MKMatthew Koshy
Matthew Koshy
DRDamiano Rondelli
Damiano Rondelli
We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between January 2014 and March 2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor-specific antibodies (DSAs), and 34% declined to proceed to HSCT. All 10 patients who were transplanted received peripheral blood stem cells. The initial 2 were conditioned with alemtuzumab/total body irradiation (TBI) 3 Gy followed by post-transplant cyclophosphamide and failed to engraft. The next 8 patients received the regimen developed at Johns Hopkins University with TBI 3 Gy. Granulocyte colony-stimulating factor was administered from day +12 in those with HbS < 30%. All 8 patients engrafted with a median time to neutrophil >.5 × 109/L of 22 days (range, 18 to 23). One patient subsequently lost the graft, and 7 (87.5%) maintained >95% donor cell chimerism at 1-year post-HSCT. Two patients developed acute graft-versus-host disease (GVHD) of at least grade II. One had chronic GVHD and died >1 year after HSCT of unknown causes. With a median follow-up of 16 months (range, 11 to 29), 7 patients (87.5%) are alive. Our findings suggest that limited insurance coverage, high rate of DSAs, and patient declining HSCT may limit the availability of haploidentical HSCT in adult SCD patients. The modified Hopkins regimen used here demonstrates high engraftment and low morbidity rates and should be tested in larger, multicenter, prospective clinical trials.

1 December 2014 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
PPPritesh Patel
Pritesh Patel
BABulent Aydogan
Bulent Aydogan
MKMatthew Koshy
Matthew Koshy
DMDolores Mahmud
Dolores Mahmud
AOAnnie Oh
Annie Oh
DRDamiano Rondelli
Damiano Rondelli
Here we examined the addition of intensity-modulated total marrow irradiation (TMI) delivered using a linear accelerator to a myeloablative chemotherapy conditioning regimen before allogeneic hematopoietic stem cell transplantation (HSCT). In this phase I study, we enrolled 14 patients with high-risk hematologic malignancies who received escalating doses of TMI at 3 Gy (n = 3), 6 Gy (n = 3), 9 Gy (n = 6), and 12 Gy (n = 2) in combination with intravenous (i.v.) fludarabine 160 mg/m(2) and targeted busulfan (area under the curve, 4800 μM*minute). Peripheral blood mobilized stem cells were obtained from HLA-matched related (n = 9) or unrelated (n = 4) or 1 antigen-mismatched unrelated (n = 1) donors. All patients rapidly engrafted and recovered their immune cells. Overall, Bearman extrahematologic toxicity were limited to grades 1 or 2, with oral mucositis grade 1 in 64% and grade 2 in 36% of the patients. With a median follow-up of 1126 days (range, 362 to 1469) for living patients, the overall survival was 50% and relapse-free survival was 43%. Of 7 deaths, 3 were due to relapse and 4 to transplantation-related complications. We conclude that 9 Gy TMI can be combined with myeloablative chemotherapy in the design of new preparative regimens for HSCT. This study was registered at clinicaltrials.gov as NCT00988013.

11 February 2008 in Bone Marrow Transplantation
Verified
Journal Article
Open access
SCS Chunduri
S Chunduri
LDL C Dobogai
L C Dobogai
DPD Peace
D Peace
YSY Saunthararajah
Y Saunthararajah
JQJohn Quigley
John Quigley
DRD Rondelli
D Rondelli
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.